• April 10, 2025

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC’s Promise as a Disease-Modifying ALS Treatment

Read More

• December 24, 2024

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Read More

• December 11, 2024

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Read More

• December 2, 2024

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Read More

• October 24, 2024

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Read More

• October 15, 2024

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Read More

• October 7, 2024

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Read More

• September 24, 2024

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer’s

Read More

• August 7, 2024

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Read More

• July 9, 2024

NeuroSense’s PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Read More

• July 1, 2024

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS

Read More

• May 14, 2024

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

Read More

• April 18, 2024

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Read More

• December 14, 2023

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Read More

• December 5, 2023

NeuroSense’s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Read More

• November 6, 2023

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

Read More

• October 4, 2023

NeuroSense’s PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

Read More

• September 20, 2023

European Medicines Agency Grants NeuroSense SME Status

Read More

• September 19, 2023

NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC

Read More

• September 6, 2023

NeuroSense to Host Investor Webinar on September 12, 2023

Read More